Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SNRS- Sunrise Technologies -- Ignore unavailable to you. Want to Upgrade?

To: admr who wrote (1487)	8/14/1998 1:15:00 PM
From: Joe	Read Replies (1) \| Respond to of 4140

I don't know if Visx gets a per use fee from others. Pillar Point (Visx & Summit) licensed the others and there must have been a requirement for a per use fee but don't know if they collect per use. Sunrise is in a unique position since they hold all the patents and, to date, there has been no threat of infringement (except for the early unsuccessful effort by Summit.) While the technology is not all that difficult to develop, IMO no one would expend the funds to do so with such a wall of patents that have been granted in the US and abroad. So if Sunrise licenses others, it will be because they want others to have the technology and not because they have been challenged by a competitor. Again this is just opinion, but when a company is in this position, they usually don't grant licenses. Regards, Joe